Table 2 Demographic and clinical characteristics of patients with EH with and without OP
Non-OP subgroup (N = 296) | OP subgroup (N = 129) | Test value | p | |
|---|---|---|---|---|
Sex | χ2 = 0.228 | 0.633 | ||
Male | 80 (27.0%) | 32 (24.8%) | ||
Female | 216 (73.0%) | 97 (75.2%) | ||
Age (years) | χ2 = 9.015 | 0.011 | ||
50–59 | 69a (23.3%) | 17b (13.2%) | ||
60–69 | 154a (52.0%) | 65a (50.4%) | ||
70–79 | 73a (24.7%) | 47b (36.4%) | ||
Body weight (kg) | 65.86 ± 9.84 | 66.80 ± 10.71 | U = 19,583.000 | 0.673 |
Fracture history | χ2 = 3.934 | 0.047 | ||
None | 237 (80.1%) | 92 (71.3%) | ||
Yes | 59 (19.9%) | 37 (28.7%) | ||
Nocturnal urination frequency | χ2 = 7.461 | 0.024 | ||
None | 82a (27.7%) | 20b (15.5%) | ||
1–2 times | 159a (53.7%) | 79a (61.2%) | ||
3 or more | 55a (18.6%) | 30a (23.3%) | ||
Depression/anxiety status | χ2 = 8.751 | 0.013 | ||
None | 231a (78.3%) | 84b (65.1%) | ||
Mild | 57a (19.3%) | 38a (29.5%) | ||
Moderate | 7a (2.4%) | 7a (5.4%) | ||
Course of hypertension | χ2 = 12.669 | 0.005 | ||
2–5 years | 126a (42.6%) | 32b (24.8%) | ||
6–10 years | 88a (29.7%) | 49a (38.0%) | ||
11–19 years | 31a (10.5%) | 21a (16.3%) | ||
more than 20 years | 51a (17.2%) | 27a (20.9%) | ||
Drug combination | χ2 = 4.770 | 0.029 | ||
Only one | 264 (89.2%) | 105 (81.4%) | ||
2 or 3 | 32 (10.8%) | 24 (18.6%) | ||
Types of Antihypertensive medication use | χ2= 36.722 | < 0.001 | ||
Irregular use | 13 (4.4%) | 17 (13.2%) | ||
Amlodipine | 125 (42.2%) | 77 (59.7%) | ||
Nifedipine | 12 (4.1%) | 8 (6.2%) | ||
Propranolol | 27 (9.1%) | 5 (3.9%) | ||
Captopril | 26 (8.8%) | 5 (3.9%) | ||
Valsartan | 71 (24.0%) | 9 (7.0%) | ||
Proprietary Chinese Medicine (pCM) | 22 (7.4%) | 8 (6.2%) | ||
CR (µmol/L) | 73.95 ± 18.11 | 69.35 ± 17.05 | U = 15,489.000 | 0.002 |
eGFR (mL/min/1.73 m2) | χ2 = 0.007 | 0.934 | ||
≥ 60 | 276 (93.24%) | 120 (93.02%) | ||
< 60 | 20 (6.76%) | 9 (6.98%) | ||